Prognostic predictors for patients with hepatocellular carcinoma receiving adjuvant transcatheter arterial chemoembolization

Jingxian Gu; Xing Zhang; Ruixia Cui; Jia Zhang; Zhixin Wang; Yifan Jia; Runchen Miao; Yanyan Dong; Xiaohua Ma; Haining Fan; Haijiu Wang; Li Ren; Yiming Li; Wenquan Niu; Jingyao Zhang; Kai Qu; Chang Liu

doi:10.1097/MEG.0000000000001346

Prognostic predictors for patients with hepatocellular carcinoma receiving adjuvant transcatheter arterial chemoembolization

Jingxian Gu
, Xing Zhang
, Ruixia Cui
, Jia Zhang
, Zhixin Wang
, Yifan Jia
, Runchen Miao
, Yanyan Dong
, Xiaohua Ma
, Haining Fan
, Haijiu Wang
, Li Ren
, Yiming Li
, Wenquan Niu
, Jingyao Zhang
, Kai Qu
, Chang Liu

Health Science Center

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

ObjectivesWe aimed to confirm the clinical effectiveness of postoperative adjuvant transcatheter arterial chemoembolization (PA-TACE) in patients with hepatocellular carcinoma after liver resection, and further identify the patients who could benefit most from PA-TACE.Patients and methodsPropensity score matching at a ratio of 1: 2 was used between hepatectomy patients with and without receiving PA-TACE. Kaplan-Meier analysis was performed to compare overall survival and recurrence-free survival between two groups. Univariate COX regression and stratified analyses were performed to screen and identify survival predictors for PA-TACE patients. The identified predictive markers were validated in an external cohort.ResultsThe propensity analysis matched 116 patients in PA-TACE group to 232 in the control group. Visible protective effect of PA-TACE was shown by survival curves in matched series (log-rank P=0.009 and 0.008), with hazard ratio of being 0.599 (95% confidence interval: 0.420-0.855) and 0.623 (95% confidence interval: 0.449-0.866), respectively, for overall survival and recurrence-free survival. The identified prognostic predictors for PA-TACE included TNM stage, tumor size and number, hepatitis B infection, spleen diameter, preoperative serum α-fetoprotein, alkaline phosphatase, γ-glutamyl transpeptidase and monocyte, and three risk signatures (aspartate aminotransferase-to-alanine aminotransferase ratio, neutrophil-to-lymphocyte ratio, and systemic immune-inflammation index).ConclusionThe treatment effectiveness of adjuvant transcatheter arterial chemoembolization for patients with hepatocellular carcinoma after surgery was validated in this study, and the best candidates for PA-TACE were identified as well, including patients with late-stage tumor, portal hypertension, and high preoperative serum levels of α-fetoprotein, alkaline phosphatase, γ-glutamyl transpeptidase, and monocytes.

Original language	English
Pages (from-to)	836-844
Number of pages	9
Journal	European Journal of Gastroenterology and Hepatology
Volume	31
Issue number	7
DOIs	https://doi.org/10.1097/MEG.0000000000001346
State	Published - 1 Jul 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

hepatocellular carcinoma
postoperative adjuvant transcatheter arterial chemoembolization
prognostic predictor
propensity score matching

Access to Document

10.1097/MEG.0000000000001346

Cite this

Gu, J., Zhang, X., Cui, R., Zhang, J., Wang, Z., Jia, Y., Miao, R., Dong, Y., Ma, X., Fan, H., Wang, H., Ren, L., Li, Y., Niu, W., Zhang, J., Qu, K., & Liu, C. (2019). Prognostic predictors for patients with hepatocellular carcinoma receiving adjuvant transcatheter arterial chemoembolization. European Journal of Gastroenterology and Hepatology, 31(7), 836-844. https://doi.org/10.1097/MEG.0000000000001346

@article{78b838257d5c42f8940e4b7c48da206b,

title = "Prognostic predictors for patients with hepatocellular carcinoma receiving adjuvant transcatheter arterial chemoembolization",

abstract = "ObjectivesWe aimed to confirm the clinical effectiveness of postoperative adjuvant transcatheter arterial chemoembolization (PA-TACE) in patients with hepatocellular carcinoma after liver resection, and further identify the patients who could benefit most from PA-TACE.Patients and methodsPropensity score matching at a ratio of 1: 2 was used between hepatectomy patients with and without receiving PA-TACE. Kaplan-Meier analysis was performed to compare overall survival and recurrence-free survival between two groups. Univariate COX regression and stratified analyses were performed to screen and identify survival predictors for PA-TACE patients. The identified predictive markers were validated in an external cohort.ResultsThe propensity analysis matched 116 patients in PA-TACE group to 232 in the control group. Visible protective effect of PA-TACE was shown by survival curves in matched series (log-rank P=0.009 and 0.008), with hazard ratio of being 0.599 (95\% confidence interval: 0.420-0.855) and 0.623 (95\% confidence interval: 0.449-0.866), respectively, for overall survival and recurrence-free survival. The identified prognostic predictors for PA-TACE included TNM stage, tumor size and number, hepatitis B infection, spleen diameter, preoperative serum α-fetoprotein, alkaline phosphatase, γ-glutamyl transpeptidase and monocyte, and three risk signatures (aspartate aminotransferase-to-alanine aminotransferase ratio, neutrophil-to-lymphocyte ratio, and systemic immune-inflammation index).ConclusionThe treatment effectiveness of adjuvant transcatheter arterial chemoembolization for patients with hepatocellular carcinoma after surgery was validated in this study, and the best candidates for PA-TACE were identified as well, including patients with late-stage tumor, portal hypertension, and high preoperative serum levels of α-fetoprotein, alkaline phosphatase, γ-glutamyl transpeptidase, and monocytes.",

keywords = "hepatocellular carcinoma, postoperative adjuvant transcatheter arterial chemoembolization, prognostic predictor, propensity score matching",

author = "Jingxian Gu and Xing Zhang and Ruixia Cui and Jia Zhang and Zhixin Wang and Yifan Jia and Runchen Miao and Yanyan Dong and Xiaohua Ma and Haining Fan and Haijiu Wang and Li Ren and Yiming Li and Wenquan Niu and Jingyao Zhang and Kai Qu and Chang Liu",

year = "2019",

month = jul,

day = "1",

doi = "10.1097/MEG.0000000000001346",

language = "英语",

volume = "31",

pages = "836--844",

journal = "European Journal of Gastroenterology and Hepatology",

issn = "0954-691X",

publisher = "Lippincott Williams and Wilkins",

number = "7",

}

Gu, J, Zhang, X, Cui, R, Zhang, J, Wang, Z, Jia, Y, Miao, R, Dong, Y, Ma, X, Fan, H, Wang, H, Ren, L, Li, Y, Niu, W, Zhang, J , Qu, K & Liu, C 2019, 'Prognostic predictors for patients with hepatocellular carcinoma receiving adjuvant transcatheter arterial chemoembolization', European Journal of Gastroenterology and Hepatology, vol. 31, no. 7, pp. 836-844. https://doi.org/10.1097/MEG.0000000000001346

TY - JOUR

T1 - Prognostic predictors for patients with hepatocellular carcinoma receiving adjuvant transcatheter arterial chemoembolization

AU - Gu, Jingxian

AU - Zhang, Xing

AU - Cui, Ruixia

AU - Zhang, Jia

AU - Wang, Zhixin

AU - Jia, Yifan

AU - Miao, Runchen

AU - Dong, Yanyan

AU - Ma, Xiaohua

AU - Fan, Haining

AU - Wang, Haijiu

AU - Ren, Li

AU - Li, Yiming

AU - Niu, Wenquan

AU - Zhang, Jingyao

AU - Qu, Kai

AU - Liu, Chang

PY - 2019/7/1

Y1 - 2019/7/1

N2 - ObjectivesWe aimed to confirm the clinical effectiveness of postoperative adjuvant transcatheter arterial chemoembolization (PA-TACE) in patients with hepatocellular carcinoma after liver resection, and further identify the patients who could benefit most from PA-TACE.Patients and methodsPropensity score matching at a ratio of 1: 2 was used between hepatectomy patients with and without receiving PA-TACE. Kaplan-Meier analysis was performed to compare overall survival and recurrence-free survival between two groups. Univariate COX regression and stratified analyses were performed to screen and identify survival predictors for PA-TACE patients. The identified predictive markers were validated in an external cohort.ResultsThe propensity analysis matched 116 patients in PA-TACE group to 232 in the control group. Visible protective effect of PA-TACE was shown by survival curves in matched series (log-rank P=0.009 and 0.008), with hazard ratio of being 0.599 (95% confidence interval: 0.420-0.855) and 0.623 (95% confidence interval: 0.449-0.866), respectively, for overall survival and recurrence-free survival. The identified prognostic predictors for PA-TACE included TNM stage, tumor size and number, hepatitis B infection, spleen diameter, preoperative serum α-fetoprotein, alkaline phosphatase, γ-glutamyl transpeptidase and monocyte, and three risk signatures (aspartate aminotransferase-to-alanine aminotransferase ratio, neutrophil-to-lymphocyte ratio, and systemic immune-inflammation index).ConclusionThe treatment effectiveness of adjuvant transcatheter arterial chemoembolization for patients with hepatocellular carcinoma after surgery was validated in this study, and the best candidates for PA-TACE were identified as well, including patients with late-stage tumor, portal hypertension, and high preoperative serum levels of α-fetoprotein, alkaline phosphatase, γ-glutamyl transpeptidase, and monocytes.

AB - ObjectivesWe aimed to confirm the clinical effectiveness of postoperative adjuvant transcatheter arterial chemoembolization (PA-TACE) in patients with hepatocellular carcinoma after liver resection, and further identify the patients who could benefit most from PA-TACE.Patients and methodsPropensity score matching at a ratio of 1: 2 was used between hepatectomy patients with and without receiving PA-TACE. Kaplan-Meier analysis was performed to compare overall survival and recurrence-free survival between two groups. Univariate COX regression and stratified analyses were performed to screen and identify survival predictors for PA-TACE patients. The identified predictive markers were validated in an external cohort.ResultsThe propensity analysis matched 116 patients in PA-TACE group to 232 in the control group. Visible protective effect of PA-TACE was shown by survival curves in matched series (log-rank P=0.009 and 0.008), with hazard ratio of being 0.599 (95% confidence interval: 0.420-0.855) and 0.623 (95% confidence interval: 0.449-0.866), respectively, for overall survival and recurrence-free survival. The identified prognostic predictors for PA-TACE included TNM stage, tumor size and number, hepatitis B infection, spleen diameter, preoperative serum α-fetoprotein, alkaline phosphatase, γ-glutamyl transpeptidase and monocyte, and three risk signatures (aspartate aminotransferase-to-alanine aminotransferase ratio, neutrophil-to-lymphocyte ratio, and systemic immune-inflammation index).ConclusionThe treatment effectiveness of adjuvant transcatheter arterial chemoembolization for patients with hepatocellular carcinoma after surgery was validated in this study, and the best candidates for PA-TACE were identified as well, including patients with late-stage tumor, portal hypertension, and high preoperative serum levels of α-fetoprotein, alkaline phosphatase, γ-glutamyl transpeptidase, and monocytes.

KW - hepatocellular carcinoma

KW - postoperative adjuvant transcatheter arterial chemoembolization

KW - prognostic predictor

KW - propensity score matching

UR - https://www.scopus.com/pages/publications/85064623255

U2 - 10.1097/MEG.0000000000001346

DO - 10.1097/MEG.0000000000001346

M3 - 文章

C2 - 30614882

AN - SCOPUS:85064623255

SN - 0954-691X

VL - 31

SP - 836

EP - 844

JO - European Journal of Gastroenterology and Hepatology

JF - European Journal of Gastroenterology and Hepatology

IS - 7

ER -

Prognostic predictors for patients with hepatocellular carcinoma receiving adjuvant transcatheter arterial chemoembolization

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this